An Open-Label Trial of Donepezil in Fragile X Syndrome
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
Fragile X syndrome is the most common known inherited cause of neurodevelopmental disability.
Functional magnetic resonance imaging (fMRI) studies from our laboratory indicate that
specific brain regions using the neurochemical, acetylcholine, show significantly reduced
activation during learning. Since donepezil is a medication that enhances acetylcholine
function in the brain, the purpose of this study is to determine if donepezil has any
beneficial effect on behavior or cognition in subjects with fragile X syndrome.